Alisha Daniels
A5045080976- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Functional Brain Connectivity Studies
- Bioinformatics and Genomic Networks
- Advanced Neuroimaging Techniques and Applications
- Parkinson's Disease Mechanisms and Treatments
- Resilience and Mental Health
- Ubiquitin and proteasome pathways
- Optimism, Hope, and Well-being
- Prion Diseases and Protein Misfolding
- Down syndrome and intellectual disability research
- Genetic Associations and Epidemiology
- Attention Deficit Hyperactivity Disorder
- Cancer Genomics and Diagnostics
- Neurological Disease Mechanisms and Treatments
- Renal cell carcinoma treatment
- Endoplasmic Reticulum Stress and Disease
- Amyotrophic Lateral Sclerosis Research
- Bipolar Disorder and Treatment
- Neuroinflammation and Neurodegeneration Mechanisms
- Frailty in Older Adults
- Tryptophan and brain disorders
- Mitochondrial Function and Pathology
- Pancreatic and Hepatic Oncology Research
- Genetics and Neurodevelopmental Disorders
Washington University in St. Louis
2022-2025
University of Ulsan
2024
Asan Medical Center
2024
Dankook University
2024
Ulsan College
2024
Alzheimer’s Disease Neuroimaging Initiative
2023
University of Florida
2019
One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of pathology are important for health care planning clinical trial design. To estimate the prevalence abnormality persons with normal cognition, subjective cognitive decline, mild impairment, or AD dementia to examine potential implications cutoff methods,...
Abstract The Dominantly Inherited Alzheimer Network (DIAN) is an international collaboration studying autosomal dominant disease (ADAD). ADAD arises from mutations occurring in three genes. Offspring families have a 50% chance of inheriting their familial mutation, so non-carrier siblings can be recruited for comparisons case–control studies. age onset highly predictable within families, allowing researchers to estimate individual’s point the trajectory. These characteristics allow candidate...
Amyloid beta and tau pathology are the hallmarks of sporadic Alzheimer's disease (AD) autosomal dominant AD (ADAD). However, Lewy body (LBP) is found in ≈ 50% ADAD brains.
Abstract We present a comprehensive global analysis of genetic variants associated with autosomal-dominant Alzheimer's disease (ADAD). A total 550 in the APP, PSEN1, and PSEN2 genes were identified, which 279 classified as pathogenic or likely based on ACMG-AMP criteria, utilizing data from Dominantly Inherited Alzheimer Network (DIAN), literature, public databases. Symptomatic age at onset (AAO) was estimated for 227 these variants, allowing detailed characterization their frequency,...
This study explored the role of ubiquitin-proteasome system (UPS) in dominantly inherited Alzheimer's disease (DIAD) by examining changes cerebrospinal fluid (CSF) levels UPS proteins along with progression, AD imaging biomarkers (PiB PET, tau PET), neurodegeneration measures (MRI, FDG and Clinical Dementia Rating
Abstract INTRODUCTION Studies suggest distinct differences in the development, presentation, progression, and response to treatment of Alzheimer's disease (AD) between females males. We investigated sex cognition, neuroimaging, fluid biomarkers dominantly inherited AD (DIAD). METHODS Three hundred twenty‐five mutation carriers (55% female) one eighty‐six non‐carriers (58% Dominantly Inherited Alzheimer Network Observational Study were analyzed. Linear mixed models Spearman's correlation...
BackgroundNeuroimaging studies often quantify tau burden in standardized brain regions to assess Alzheimer disease (AD) progression. However, this method ignores another key biological process which spreads additional regions. We have developed a metric for calculating the extent pathology has spread throughout and evaluate relationship between across early stages of AD.Methods445 cross-sectional participants (aged ≥ 50) who had MRI, amyloid PET, clinical testing were separated into...
Abstract This manuscript describes and summarizes the Dominantly Inherited Alzheimer Network Observational Study (DIAN Obs), highlighting wealth of longitudinal data, samples, results from this human cohort study brain aging a rare monogenic form Alzheimer’s disease (AD). DIAN Obs is an international collaborative initiated in 2008 with support National Institute on Aging (NIA), designed to obtain comprehensive uniform data biology function individuals at risk for autosomal dominant AD...
Abstract INTRODUCTION We investigated longitudinal associations between self‐reported exercise and Alzheimer's disease (AD)‐related biomarkers in individuals with autosomal dominant AD (ADAD) mutations. METHODS Participants were 308 ADAD mutation carriers aged 39.7 ± 10.8 years from the Dominantly Inherited Network. Weekly volume was measured via questionnaire brain (magnetic resonance imaging), cerebrospinal fluid biomarkers, amyloid beta (Aβ) by positron emission tomography investigated....
Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying onset of symptoms asymptomatic people is unknown. The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) an ongoing platform trial assessing safety and efficacy multiple investigational products participants with dominantly inherited disease (DIAD) caused mutations. On basis findings amyloid downstream biological effects from...
Disease-modifying therapies for Alzheimer's disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track benefit of such interventions, fluid biomarkers great importance, with neurofilament light chain protein (NfL) showing promise monitoring neurodegeneration and predicting cognitive outcomes. Here, we update complement previous findings from Dominantly Inherited Alzheimer Network Observational Study by using matched cross-sectional longitudinal...
Abstract Carriers of mutations responsible for dominantly inherited Alzheimer disease provide a unique opportunity to study potential imaging biomarkers. Biomarkers based on routinely acquired clinical MR images, could supplement the extant invasive or logistically challenging) biomarker studies. We used 1104 longitudinal MR, 324 amyloid beta, and 87 tau positron emission tomography sessions from 525 participants enrolled in Dominantly Inherited Network Observational Study extract novel...
Abstract Hub regions in the brain, recognized for their roles ensuring efficient information transfer, are vulnerable to pathological alterations neurodegenerative conditions, including Alzheimer’s disease (AD). Computational simulations and animal experiments have hinted at theory of activity-dependent degeneration as cause this hub vulnerability. However, two critical issues remain unresolved. First, past research has not clearly distinguished between scenarios: facing a higher risk...
It remains unknown whether the associations between protective lifestyles and sporadic dementia risk reported in observational studies also affect age at symptom onset (AAO) autosomal dominant Alzheimer disease (ADAD) with predominant genetic influences. We investigated resilience-related life experiences interindividual AAO variability ADAD.
Abstract Background Cognitive reserve (CR) has emerged as a critical factor in understanding clinical‐cognitive heterogeneity Alzheimer’s disease (AD). However, there is limited evidence of the effect CR during asymptomatic phases disease, age at symptom onset (AAO) and longitudinal decline. In this study, we elucidate impact on AAO decline rate using Dominantly Inherited Disease (DIAD) progression model. Methods DIAD participants were selected from Alzheimer Network (DIAN) study 1 . Using...
Abstract Hub regions in the brain, recognized for their roles ensuring efficient information transfer, are vulnerable to pathological alterations neurodegenerative conditions, including Alzheimer Disease (AD). Given essential role neural communication, disruptions these hubs have profound implications overall brain network integrity and functionality. disruption, or targeted impairment of functional connectivity at hubs, is AD patients. Computational models paired with evidence from animal...
Abstract Background Studies suggest distinct differences in the development, presentation and longitudinal progression of Alzheimer’s Disease (AD) between women men. However, most these sex‐specific have been explored symptomatic stages sporadic AD. We investigated cross‐sectional sex clinical‐cognitive assessments as well fluid imaging biomarkers spectrum dominantly inherited AD (DIAD). Method 319 DIAD mutation carriers Dominantly Inherited Alzheimer Network‐Observational study (DIAN‐OBS)...
Abstract Background Both sporadic and dominantly inherited Alzheimer’s disease (DIAD) present with similar pathobiology symptoms. A loss of proteostasis in AD has been identified recent studies highlighting the role ubiquitin‐dependent mechanisms brain homeostasis neurodegenerative diseases. The Ubiquitin Proteasome System (UPS) is responsible for degradation misfolded or aggregated proteins via an ATP‐dependent proteolytic mechanism. This process involves a cascade ubiquitin transfer steps...
Background: It remains unknown whether associations between protective lifestyles and the risk of sporadic dementia in observational studies also affect age at symptom onset (AAO) autosomal dominant Alzheimer’s disease (ADAD), which genetic influences predominate. We investigated resilience-related during preclinical period interindividual variability AAO ADAD.Methods: performed a longitudinal confirmatory analysis data from 320 carriers 209 noncarriers Dominantly Inherited Alzheimer Network...
TPS476 Background: Neoadjuvant treatment for borderline resectable pancreatic cancer (PCa) is increasing in acceptability, but a standard regimen has yet to be established. Multiple studies have demonstrated feasibility and effectiveness of the FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin irinotecan) perioperative setting. However, often requires dose modifications, delays growth factor support due excessive toxicity which can complicate care delivery when given neoadjuvantly....